Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin (TAZ/PIPC) in 3,952 bacterial strains isolated in 2012 were conducted in Japan. β-lactamase production was investigated in over 80% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Providencia spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group. Extended spectrum β-lactamase-producing strains in E. coli, K. pneumoniae and P. mirabilis were 19.0%, 7.2% and 8.2%, respectively. Metallo-β-lactamase producers in P. aeruginosa and Acinetobacter spp. were 1.0% and 0.4%, respectively, and no strain of E. cloacae and S. marcescens was detected. Susceptibility of 3,952 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute or European Committee on Antimicrobial Susceptibility testing were distributed from 79.2% in E.cloacae to 100% in methicillin-susceptible S. aureus, coagulase-negative staphylococci, M. catarrhalis, P. mirabilis, indole-positive Proteus spp. and H. influenzae including β-lactamase-negative ampicillin-resistant strains. When compared with those in previous investigations conducted in 2010, the susceptibility to TAZ/PIPC had not changed. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for infectious diseases.
|Number of pages||13|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - Jul 2016|
ASJC Scopus subject areas
- Pharmacology (medical)